



Kristen N Ganjoo

Associate Professor of Medicine (Oncology) at the Stanford University Medical Center

Medicine - Oncology

 Curriculum Vitae available Online

CLINICAL OFFICES

- **Stanford Comprehensive Cancer Center**

875 Blake Wilbur Dr

MC 5826

Stanford, CA 94305

Tel (650) 498-6000

Fax (650) 725-3321

Bio

CLINICAL FOCUS

- Cancer > Lymphoma
- Cancer > Sarcoma
- Soft Tissue Sarcoma
- Gastrointestinal Stromal Tumors
- Ewing's Sarcoma
- Osteosarcoma
- Medical Oncology
- Uterine leiomyosarcoma
- Leiomyosarcoma
- Liposarcoma
- Synovial sarcoma

ACADEMIC APPOINTMENTS

- Associate Professor - Med Center Line, Medicine - Oncology
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Assistant Professor of Medicine, Indiana University, (2000-2004)
- Assistant Professor of Medicine, Stanford University, (2004-2015)
- Associate Professor of Medicine, Stanford University, (2015- present)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Associate Member, American Society of Clinical Oncology (1998 - present)
- Investigator, Sarcoma Alliance for Research through Collaboration (SARC) (2008 - present)
- Physician Leader, Stanford Cancer Center- Sarcoma (2008 - present)
- Board Member, National Comprehensive Cancer Network Task Force (NCCN)-Soft Tissue Sarcoma (2009 - present)
- Clinical Research Group Leader-Sarcoma, Stanford University (2010 - present)
- Member, Connective Tissue Oncology Society (CTOS) (2010 - present)
- Member, Institutional Review Board- Stanford (2012 - present)

- Member, Scientific Review Board- Stanford Cancer Institute (2013 - present)

PROFESSIONAL EDUCATION

- Board Certification: Medical Oncology, American Board of Internal Medicine (2000)
- Fellowship: Indiana University School Of Medicine (2000) IN
- Residency: Indiana University (1997) IN
- Internship: Indiana University (1995) IN
- Medical Education: University of South Alabama Medical Center (1994) AL
- BS, UC Davis , Biological Sciences (1989)

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Clinical research with new and novel therapies for sarcomas including anti-angiogenesis agents and targeted agents. .

Publications

PUBLICATIONS

- **NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021.** *Journal of the National Comprehensive Cancer Network : JNCCN*
von Mehren, M., Kane, J. M., Bui, M. M., Choy, E., Connelly, M., Dry, S., Ganjoo, K. N., George, S., Gonzalez, R. J., Heslin, M. J., Homsy, J., Keedy, V., Kelly, et al
2020; 18 (12): 1604–12
- **Detection of Circulating Tumor DNA in Patients With Uterine Leiomyomas** *JCO PRECISION ONCOLOGY*
Przybyl, J., Spans, L., Lum, D. A., Zhu, S., Vennam, S., Forgo, E., Varma, S., Ganjoo, K., Hastie, T., Bowen, R., Debiec-Rychter, M., van de Rijn, M.
2019; 3
- **Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma** *CLINICAL CANCER RESEARCH*
Przybyl, J., Chabon, J. J., Spans, L., Ganjoo, K. N., Vennam, S., Newman, A. M., Forgo, E., Varma, S., Zhu, S., Debiec-Rychter, M., Alizadeh, A. A., Diehn, M., van de Rijn, et al
2018; 24 (11): 2688–99
- **Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma** *JOURNAL OF CLINICAL ONCOLOGY*
Chawla, S. P., Cranmer, L. D., Van Tine, B. A., Reed, D. R., Okuno, S. H., Butrynski, J. E., Adkins, D. R., Hendifar, A. E., Kroll, S., Ganjoo, K. N.
2014; 32 (29): 3299-?
- **A Phase 2 Trial of R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R), in Patients With Recurrent or Refractory Rhabdomyosarcoma, Osteosarcoma, Synovial Sarcoma, and Other Soft Tissue Sarcomas Results of a Sarcoma Alliance for Research Through Collaboration Study** *CANCER*
Pappo, A. S., Vassal, G., Crowley, J. J., Bolejack, V., Hogendoorn, P. C., Chugh, R., Ladanyi, M., Grippo, J. F., Dall, G., Staddon, A. P., Chawla, S. P., Maki, R. G., Araujo, et al
2014; 120 (16): 2448-2456
- **Gastrointestinal stromal tumors, version 2.2014.** *Journal of the National Comprehensive Cancer Network*
von Mehren, M., Randall, R. L., Benjamin, R. S., Boles, S., Bui, M. M., Casper, E. S., Conrad, E. U., DeLaney, T. F., Ganjoo, K. N., George, S., Gonzalez, R. J., Heslin, M. J., Kane, et al
2014; 12 (6): 853-862
- **Soft Tissue Sarcoma, Version 2.2014 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
von Mehren, M., Randall, R. L., Benjamin, R. S., Boles, S., Bui, M. M., Casper, E. S., Conrad, E. U., DeLaney, T. F., Ganjoo, K. N., George, S., Gonzalez, R. J., Heslin, M. J., Kane, et al

2014; 12 (4): 473-483

- **A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.** *Annals of oncology*
Ganjoo, K. N., Villalobos, V. M., Kamaya, A., Fisher, G. A., Butrynski, J. E., Morgan, J. A., Wagner, A. J., D'adamo, D., McMillan, A., Demetri, G. D., George, S.
2014; 25 (1): 236-240
- **R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study** *JOURNAL OF CLINICAL ONCOLOGY*
Pappo, A. S., Patel, S. R., Crowley, J., Reinke, D. K., Kuenkele, K., Chawla, S. P., Toner, G. C., Maki, R. G., Meyers, P. A., Chugh, R., Ganjoo, K. N., Schuetze, S. M., Juergens, et al
2011; 29 (34): 4541-4547
- **Current and Emerging Pharmacological Treatments for Gastrointestinal Stromal Tumour** *DRUGS*
Ganjoo, K. N., Patel, S.
2011; 71 (3): 321-330
- **A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma** *ONCOLOGY*
Ganjoo, K. N., Cranmer, L. D., Butrynski, J. E., Rushing, D., Adkins, D., Okuno, S. H., Lorente, G., Kroll, S., Langmuir, V. K., Chawla, S. P.
2011; 80 (1-2): 50-56
- **New Developments in Targeted Therapy for Soft Tissue Sarcoma** *CURRENT ONCOLOGY REPORTS*
Ganjoo, K. N.
2010; 12 (4): 261-265
- **Soft Tissue Sarcoma** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Demetri, G. D., Antonia, S., Benjamin, R. S., Bui, M. M., Casper, E. S., Conrad, E. U., DeLaney, T. F., Ganjoo, K. N., Heslin, M. J., Hutchinson, R. J., Kane, J. M., Letson, G. D., McGarry, et al
2010; 8 (6): 630-674
- **NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Demetri, G. D., von Mehren, M., Antonescu, C. R., DeMatteo, R. P., Ganjoo, K. N., Maki, R. G., Pisters, P. W., Raut, C. P., Riedel, R. F., Schuetze, S., Sundar, H. M., Trent, J. C., Wayne, et al
2010; 8: S1-S43
- **Antiangiogenesis Agents in the Treatment of Soft Tissue Sarcomas** *CANCER*
Ganjoo, K., Jacobs, C.
2010; 116 (5): 1177-1183
- **Trabectedin: an anticancer drug from the sea** *EXPERT OPINION ON PHARMACOTHERAPY*
Ganjoo, K. N., Patel, S. R.
2009; 10 (16): 2735-2743
- **Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec** *LEUKEMIA & LYMPHOMA*
Ganjoo, K. N., Demetri, G. D., Jacobs, C., Patel, S.
2009; 50 (11): 1882-1884
- **Ripretinib intra-patient dose escalation (IPDE) following disease progression provides clinically meaningful progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) in phase I**
Janku, F., Chi, P., Heinrich, M., von Mehren, M., Jones, R. L., Ganjoo, K., Trent, J., Gelderblom, H., Razak, A., Gordon, M., Somaiah, N., Jennings, J., Shi, et al
ELSEVIER.2020: S974-S975
- **Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Janku, F., Abdul Razak, A. R., Chi, P., Heinrich, M. C., von Mehren, M., Jones, R. L., Ganjoo, K., Trent, J., Gelderblom, H., Somaiah, N., Hu, S., Rosen, O., Su, et al
2020: JCO2000522
- **A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib vs. Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study.** *The oncologist*

- Riedel, R. F., Ballman, K. V., Attia, S., Loggers, E. T., Ganjoo, K. N., Livingston, M. B., Chow, W., Wright, J., Ward, J. H., Rushing, D., Okuno, S. H., Reed, D. R., Liebner, et al
2020
- **Long-term follow-up for duration of response (DoR) after weekly nab-sirolimus in patients with advanced malignant perivascular epithelioid cell tumors (PEComa): Results from a registrational open-label phase II trial, AMPECT.**
Wagner, A. J., Ravi, V., Riedel, R. F., Ganjoo, K. N., Van Tine, B., Chugh, R., Cranmer, L. D., Gordon, E., Hornick, J. L., Kwiatkowski, D. J., Du, H., Grigorian, B., Schmid, et al
AMER SOC CLINICAL ONCOLOGY.2020
 - **Endometriosis Malignant Transformation Review: Rhabdomyosarcoma Arising From an Endometrioma.** *JSLs : Journal of the Society of Laparoendoscopic Surgeons*
Nezhat, C., Vu, M., Vang, N., Ganjoo, K., Karam, A., Folkins, A., Nezhat, A., Nezhat, F.
; 23 (4)
 - **Nivolumab plus ipilimumab for soft tissue sarcoma: a single institution retrospective review.** *Immunotherapy*
Zhou, M., Bui, N., Bolleddu, S., Lohman, M., Becker, H. C., Ganjoo, K.
2020
 - **Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.** *JAMA*
Tap, W. D., Wagner, A. J., Schöffski, P., Martin-Broto, J., Krarup-Hansen, A., Ganjoo, K. N., Yen, C. C., Abdul Razak, A. R., Spira, A., Kawai, A., Le Cesne, A., Van Tine, B. A., Naito, et al
2020; 323 (13): 1266–76
 - **Angiosarcoma of the Breast: Management and Outcomes.** *American journal of clinical oncology*
Gutkin, P. M., Ganjoo, K. N., Lohman, M., von Eyben, R., Charville, G. W., Nazerali, R. S., Dirbas, F. M., Horst, K. C.
2020
 - **Tenosynovial giant cell tumor of the suboccipital region - A rare, benign neoplasm in this location.** *Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia*
Singh, R., Stienen, M. N., Ganjoo, K., Kolahi, K. S., Cayrol, R., Charville, G. W., Born, D. E., Zygourakis, C. C.
2020
 - **Updated results of phase 1 study of ripretinib (DCC-2618), a broad-spectrum KIT and PDGFRA inhibitor, in patients with gastrointestinal stromal tumor (GIST) by line of therapy (NCT02571036)**
Chi, P., Janku, F., Heinrich, M., Ganjoo, K., Gelderblom, H., Gordon, M., Jones, R., Razak, A., Trent, J., von Mehren, M., Hu, S., Su, Y., Ruiz-Soto, et al
AMER ASSOC CANCER RESEARCH.2019
 - **Results of the TAPPAS trial: An adaptive enrichment phase III trial of TRC105 and pazopanib (P) versus pazopanib alone in patients with advanced angiosarcoma (AS)**
Jones, R. L., Ravi, V., Brohl, A. S., Chawla, S. P., Ganjoo, K., Italiano, A., Attia, S., Burgess, M., Thornton, K., Cranmer, L., Liu, L., Theuer, C., Maki, et al
OXFORD UNIV PRESS.2019: 683
 - **Ripretinib (DCC-2618) pharmacokinetics (PK) in a Phase I study in patients with gastrointestinal stromal tumors (GIST) and other advanced malignancies: A retrospective evaluation of the PK effects of proton pump inhibitors (PPIs)**
Janku, F., Heinrich, M., Chi, P., Razak, A., von Mehren, M., Gordon, M., Ganjoo, K., Trent, J., Jones, R. L., Gelderblom, H., Running, K., Wang, J., Ruiz-Soto, et al
AMER ASSOC CANCER RESEARCH.2019
 - **ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) plus olaratumab versus dox plus PBO in patients (pts) with advanced soft tissue sarcomas (STS).**
Tap, W. D., Wagner, A. J., Papai, Z., Ganjoo, K. N., Yen, C., Schoffski, P., Razak, A., Martin Broto, J., Spira, A. I., Kawai, A., Krarup-Hansen, A., Le Cesne, A., Van Tine, et al
AMER SOC CLINICAL ONCOLOGY.2019
 - **Uterine sarcomas.** *Current problems in cancer*
Ganjoo, K. N.
2019
 - **Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma** *JOURNAL OF CLINICAL ONCOLOGY*

- Davis, L. E., Bolejack, V., Ryan, C. W., Ganjoo, K. N., Loggers, E. T., Chawla, S., Agulnik, M., Livingston, M. B., Reed, D., Keedy, V., Rushing, D., Okuno, S., Reinke, et al
2019; 37 (16): 1424-+
- **A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1(+) soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient survival.**
Chawla, S. P., Van Tine, B., Pollack, S., Ganjoo, K. N., Elias, A. D., Riedel, R. F., Attia, S., Choy, E., Okuno, S. H., Agulnik, M., von Mehren, M., Livingston, M. B., Keedy, et al
AMER SOC CLINICAL ONCOLOGY.2019
 - **A phase II study of ADI-PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma.**
Van Tine, B., Bui, N., Prudner, B., Bomalaski, J. S., Wu, B., Chawla, S. P., Ganjoo, K. N., Oppelt, P., Hirbe, A. C.
AMER SOC CLINICAL ONCOLOGY.2019
 - **Multi-institutional analysis of outcomes in patients with dedifferentiated chondrosarcoma (DDCS).**
Bui, N., Dietz, H., Hirbe, A. C., Ganjoo, K. N., Van Tine, B., Keedy, V., Davis, E. J.
AMER SOC CLINICAL ONCOLOGY.2019
 - **ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial.**
Wagner, A. J., Ravi, V., Ganjoo, K. N., Van Tine, B., Riedel, R. F., Chugh, R., Cranmer, L. D., Gordon, E., Hornick, J. L., Kwiatkowski, D. J., Du, H., Grigorian, B., Schmid, et al
AMER SOC CLINICAL ONCOLOGY.2019
 - **Responder analysis of patient-reported outcomes measurement information system (PROM'S) physical function (PF) and worst stiffness among patients with tenosynovial giant cell tumors (TGCT) in the ENLIVEN study.**
Tap, W. D., Speck, R. M., Ye, X., Palmerini, E., Stacchiotti, S., Desai, J., Wagner, A. J., Alcindor, T., Ganjoo, K. N., Broto, J., Wang, Q., Shuster, D., Gelhorn, et al
AMER SOC CLINICAL ONCOLOGY.2019
 - **Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Davis, L. E., Bolejack, V., Ryan, C. W., Ganjoo, K. N., Loggers, E. T., Chawla, S., Agulnik, M., Livingston, M. B., Reed, D., Keedy, V., Rushing, D., Okuno, S., Reinke, et al
2019; JCO1802374
 - **The Outcome of Patients With Localized Undifferentiated Pleomorphic Sarcoma of the Lower Extremity Treated at Stanford University** *AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS*
Kamat, N. V., Million, L., Yao, D., Donaldson, S. S., Mohler, D. G., van de Rijn, M., Avedian, R. S., Kapp, D. S., Ganjoo, K. N.
2019; 42 (2): 166-71
 - **Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.** *Lancet (London, England)*
Tap, W. D., Gelderblom, H., Palmerini, E., Desai, J., Bauer, S., Blay, J. Y., Alcindor, T., Ganjoo, K., Martín-Broto, J., Ryan, C. W., Thomas, D. M., Peterfy, C., Healey, et al
2019
 - **A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosis.** *Clinical sarcoma research*
Bui, N. Q., Przybyl, J., Trabucco, S. E., Frampton, G., Hastie, T., van de Rijn, M., Ganjoo, K. N.
2019; 9: 12
 - **Detection of Circulating Tumor DNA in Patients With Uterine Leiomyomas.** *JCO precision oncology*
Przybyl, J., Spans, L., Lum, D. A., Zhu, S., Vennam, S., Forgó, E., Varma, S., Ganjoo, K., Hastie, T., Bowen, R., Debiec-Rychter, M., van de Rijn, M.
2019; 3
 - **The Outcome of Patients With Localized Undifferentiated Pleomorphic Sarcoma of the Lower Extremity Treated at Stanford University.** *American journal of clinical oncology*
Kamat, N. V., Million, L., Yao, D., Donaldson, S. S., Mohler, D. G., van de Rijn, M., Avedian, R. S., Kapp, D. S., Ganjoo, K. N.
2018
 - **Initial results of phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens**
George, S., Heinrich, M., Chi, P., Razak, A., von Mehren, M., Gordon, M., Ganjoo, K. N., Somaiah, N., Trent, J. C., Ahnert, J., Wolf, J., Ruiz-Soto, R., Rosen, et al

OXFORD UNIV PRESS.2018

- **Initial results of phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens.** *Annals of oncology : official journal of the European Society for Medical Oncology*
George, S., Heinrich, M., Chi, P., Razak, A., von Mehren, M., Gordon, M., Ganjoo, K. N., Somaiah, N., Trent, J. C., Rodon Ahnert, J., Wolf, J., Ruiz-Soto, R., Rosen, et al
2018; 29 Suppl 8: viii576–viii577
- **Aldoxorubicin therapy for the treatment of patients with advanced soft tissue sarcoma** *FUTURE ONCOLOGY*
Seetharam, M., Kolla, K. R., Ganjoo, K. N.
2018; 14 (23): 2323–33
- **Pharmacokinetic (PK), safety, and tolerability profile of DCC-2618 in a phase I trial supports 150mg QD selected for a pivotal phase III trial in gastrointestinal stromal tumor (GIST)**
Janku, F., Heinrich, M., Razak, A., Gordon, M., Chi, P., Ganjoo, K., von Mehren, M., Somaiah, N., Lee, J., Kuida, K., Soto, R., Rosen, O., George, et al
AMER ASSOC CANCER RESEARCH.2018
- **Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib** *JAMA ONCOLOGY*
Schuetze, S. M., Bolejack, V., Thomas, D. G., von Mehren, M., Patel, S., Samuels, B., Choy, E., D'Amato, G., Staddon, A. P., Ganjoo, K. N., Chow, W. A., Rushing, D. A., Forscher, et al
2018; 4 (6): 814–20
- **Mutation profile of drug resistant gastrointestinal stromal tumor (GIST) patients (pts) enrolled in the phase 1 study of DCC-2618.**
George, S., Heinrich, M. C., Razak, A., Chi, P., Gordon, M. S., Ganjoo, K. N., von Mehren, M., Somaiah, N., Trent, J. C., Su, Y., Ruiz-Soto, R., Rosen, O., Janku, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **Decreased lymphocyte count at diagnosis as a marker for worse outcome in localized sarcoma.**
Bui, N., Henry, S., Ganjoo, K. N.
AMER SOC CLINICAL ONCOLOGY.2018
- **Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-rapamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa).**
Wagner, A. J., Riedel, R. F., Van Tine, B., Chugh, R., Ganjoo, K. N., Cranmer, L. D., Pollack, S., Sankhala, K., Gordon, E., Ravi, V., Hornick, J. L., Kwiatkowski, D. J., Grigorian, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study.**
Riedel, R. F., Ballman, K. V., Lu, Y., Attia, S., Loggers, E., Ganjoo, K. N., Livingston, M. B., Chow, W., Wright, J. A., Ward, J., Rushing, D. A., Okuno, S. H., Reed, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT).**
Tap, W. D., Gelderblom, H., Stacchiotti, S., Palmerini, E., Ferrari, S., Desai, J., Bauer, S., Blay, J., Alcindor, T., Ganjoo, K. N., Broto, J., Ryan, C. W., Shuster, et al
AMER SOC CLINICAL ONCOLOGY.2018
- **CDKN2A deletion as a prognostic marker: A clinico-genomic analysis of sarcoma patients.**
Nam Bui, Przybyl, J., Million, L., Van De Rijn, M., Ganjoo, K. N.
AMER SOC CLINICAL ONCOLOGY.2018
- **Soft Tissue Sarcoma, Version 2.2018** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
von Mehren, M., Randall, R., Benjamin, R. S., Boles, S., Bui, M. M., Ganjoo, K. N., George, S., Gonzalez, R. J., Heslin, M. J., Kane, J. M., Keedy, V., Kim, E., Koon, et al
2018; 16 (5): 536–63
- **Circulating tumor DNA levels correlate with response to treatment in LMS patients**
Przybyl, J., Chabon, J. J., Spans, L., Ganjoo, K., Vennam, S., Newman, A. M., Forgo, E., Varma, S., Zhu, S., Debiec-Rychter, M., Alizadeh, A., Diehn, M., van de Rijn, et al
AMER ASSOC CANCER RESEARCH.2018: 38–39

- **The Impact of Post-Operative Therapy on Primary Cardiac Sarcoma** *The Journal of Thoracic and Cardiovascular Surgery*
Wu, Y., Million, L., Moding, E. J., Scott, G., Berry, M., Ganjoo, K. N.
2018
- **The impact of postoperative therapy on primary cardiac sarcoma.** *The Journal of thoracic and cardiovascular surgery*
Wu, Y., Million, L., Moding, E. J., Scott, G., Berry, M., Ganjoo, K. N.
2018; 156 (6): 2194–2203
- **Combination approach for detecting different types of alterations in circulating tumor DNA in leiomyosarcoma.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Przybyl, J., Chabon, J. J., Spans, L., Ganjoo, K., Vennam, S., Newman, A. M., Forgó, E., Varma, S., Zhu, S., Debiec-Rychter, M., Alizadeh, A. A., Diehn, M., van de Rijn, et al
2018
- **Anaplastic Thyroid Cancer With Extensive Skeletal Muscle Metastases on 18F-FDG PET/CT.** *Clinical nuclear medicine*
Yurkiewicz, I. R., Ganjoo, K. N., Iagaru, A.
2018
- **A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma.** *Rare tumors*
Bui, N., Kamat, N., Ravi, V., Chawla, S., Lohman, M., Ganjoo, K. N.
2018; 10: 2036361318771771
- **Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial** *GYNECOLOGIC ONCOLOGY*
Hensley, M. L., Patel, S. R., von Mehren, M., Ganjoo, K., Jones, R. L., Staddon, A., Rushing, D., Milhem, M., Monk, B., Wang, G., McCarthy, S., Knoblauch, R. E., Parekh, et al
2017; 146 (3): 531–37
- **Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial** *LANCET ONCOLOGY*
Tap, W. D., Papai, Z., Van Tine, B. A., Attia, S., Ganjoo, K. N., Jones, R. L., Schuetze, S., Reed, D., Chawla, S. P., Riedel, R. F., Krarup-Hansen, A., Toulmonde, M., Ray-Coquard, et al
2017; 18 (8): 1089–1103
- **Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma** *BRITISH JOURNAL OF HAEMATOLOGY*
Martin, P., Chen, Z., Cheson, B. D., Robinson, K. S., Williams, M., Rajguru, S. A., Friedberg, J. W., van der Jagt, R. H., LaCasce, A. S., Joyce, R., Ganjoo, K. N., Bartlett, N. L., Lemieux, et al
2017; 178 (2): 250–56
- **A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARCO24 trial results**
Attia, S., Bolejack, V., Ganjoo, K. N., George, S., Agulnik, M., Rushing, D. A., Loggers, E., Livingston, M. B., Wright, J. A., Chawla, S. P., Okuno, S. H., Reinke, D. K., Riedel, et al
AMER SOC CLINICAL ONCOLOGY.2017
- **Phase III study of aldorubicin vs investigators' choice as treatment for relapsed/refractory soft tissue sarcomas**
Chawla, S. P., Ganjoo, K. N., Schuetze, S., Papai, Z., Van Tine, B., Choy, E., Liebner, D. A., Agulnik, M., Chawla, S., Wieland, S., Levitt, D. J.
AMER SOC CLINICAL ONCOLOGY.2017
- **Improving care with portfolio of physician-led cancer quality measures at an academic center**
Porter, J., Smith, A., Winget, M., Rosenthal, E., Seshadri, S., Vetteth, Y., Kiamanesh, E. F., Badwe, A., Advani, R. H., Buyyounouski, M. K., Coutre, S., Dorigo, O., Ganjoo, et al
AMER SOC CLINICAL ONCOLOGY.2017
- **Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors: a retrospective multicenter study** *EUROPEAN RADIOLOGY*
Ghanouni, P., Dobrotwir, A., Bazzocchi, A., Bucknor, M., Bitton, R., Rosenberg, J., Telischak, K., Busacca, M., Ferrari, S., Albisinni, U., Walters, S., Gold, G., Ganjoo, et al
2017; 27 (2): 732-740

- **Phase 2 Study of Dasatinib in Patients With Alveolar Soft Part Sarcoma, Chondrosarcoma, Chordoma, Epithelioid Sarcoma, or Solitary Fibrous Tumor** *CANCER*
Schuetz, S. M., Bolejack, V., Choy, E., Ganjoo, K. N., Staddon, A. P., Chow, W. A., Tawbi, H. A., Samuels, B. L., Patel, S. R., von Mehren, M., D'Amato, G., Leu, K. M., Loeb, et al
2017; 123 (1): 90-97
- **Concurrent Imatinib and Radiation Therapy for Unresectable and Symptomatic Desmoid Tumors.** *Sarcoma*
Moding, E. J., Million, L., Avedian, R., Ghanouni, P., Kunder, C., Ganjoo, K. N.
2017; 2017: 2316839
- **Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center** *Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center*
Porter, J. B.
2017; 13 (8): e673-e682
- **Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor.** *Cancer*
Schuetz, S. M., Bolejack, V., Choy, E., Ganjoo, K. N., Staddon, A. P., Chow, W. A., Tawbi, H. A., Samuels, B. L., Patel, S. R., von Mehren, M., D'Amato, G., Leu, K. M., Loeb, et al
2016
- **Soft Tissue Sarcoma, Version 2.2016 Clinical Practice Guidelines in Oncology** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
von Mehren, M., Randall, R. L., Benjamin, R. S., Boles, S., Bui, M. M., Conrad, E. U., Ganjoo, K. N., George, S., Gonzalez, R. J., Heslin, M. J., Kane, J. M., Koon, H., Mayerson, et al
2016; 14 (6): 758-786
- **Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors: a retrospective multicenter study.** *European radiology*
Ghanouni, P., Dobrotwir, A., Bazzocchi, A., Bucknor, M., Bitton, R., Rosenberg, J., Telischak, K., Busacca, M., Ferrari, S., Albinini, U., Walters, S., Gold, G., Ganjoo, et al
2016: -?
- **SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma.** *Cancer*
Schuetz, S. M., Wathen, J. K., Lucas, D. R., Choy, E., Samuels, B. L., Staddon, A. P., Ganjoo, K. N., von Mehren, M., Chow, W. A., Loeb, D. M., Tawbi, H. A., Rushing, D. A., Patel, et al
2016; 122 (6): 868-874
- **Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.** *Journal of clinical oncology*
Demetri, G. D., von Mehren, M., Jones, R. L., Hensley, M. L., Schuetz, S. M., Staddon, A., Milhem, M., Elias, A., Ganjoo, K., Tawbi, H., Van Tine, B. A., Spira, A., Dean, et al
2016; 34 (8): 786-793
- **First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial.** *JAMA oncology*
Chawla, S. P., Papai, Z., Mukhametshina, G., Sankhala, K., Vasylyev, L., Fedenko, A., Khamly, K., Ganjoo, K., Nagarkar, R., Wieland, S., Levitt, D. J.
2015; 1 (9): 1272-1280
- **First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma A Phase 2b Randomized Clinical Trial** *JAMA ONCOLOGY*
Chawla, S. P., Papai, Z., Mukhametshina, G., Sankhala, K., Vasylyev, L., Fedenko, A., Khamly, K., Ganjoo, K., Nagarkar, R., Wieland, S., Levitt, D. J.
2015; 1 (9): 1272-1280
- **Sarcoma Resection With and Without Vascular Reconstruction: A Matched Case-control Study** *ANNALS OF SURGERY*
Poultides, G. A., Tran, T. B., Zambrano, E., Janson, L., Mohler, D. G., Mell, M. W., Avedian, R. S., Visser, B. C., Lee, J. T., Ganjoo, K., Harris, E. J., Norton, J. A.
2015; 262 (4): 632-640
- **Combined F-18-NaF and F-18-FDG PET/CT in the Evaluation of Sarcoma Patients** *CLINICAL NUCLEAR MEDICINE*
Jackson, T., Mosci, C., von Eyben, R., Mittra, E., Ganjoo, K., Biswal, S., Gambhir, S. S., Iagaru, A.
2015; 40 (9): 720-724
- **Denosumab, a Potential Alternative to the Surgical Treatment of Distal Radius Giant Cell Tumor of Bone: Case Report.** *journal of hand surgery*

- Park, M. J., Ganjoo, K. N., Ladd, A. L.
2015; 40 (8): 1620-1624
- **Clinically Relevant Molecular Subtypes in Leiomyosarcoma.** *Clinical cancer research*
Guo, X., Jo, V. Y., Mills, A. M., Zhu, S. X., Lee, C., Espinosa, I., Nucci, M. R., Varma, S., Forgó, E., Hastie, T., Anderson, S., Ganjoo, K., Beck, et al
2015; 21 (15): 3501-3511
 - **Leiomyosarcoma: One Disease or Distinct Biologic Entities Based on Site of Origin?** *JOURNAL OF SURGICAL ONCOLOGY*
Worhunsky, D. J., Gupta, M., Gholami, S., Tran, T. B., Ganjoo, K. N., van de Rijn, M., Visser, B. C., Norton, J. A., Poultides, G. A.
2015; 111 (7): 808-812
 - **Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity Fc γ RIIIa Patients with Previously Treated Follicular Lymphoma.** *Leukemia & lymphoma*
Ganjoo, K. N., de Vos, S., Pohlman, B. L., Flinn, I. W., Forero-Torres, A., Enas, N. H., Cronier, D. M., Dang, N. H., Foon, K. A., Carpenter, S. P., Slapak, C. A., Link, B. K., Smith, et al
2015; 56 (1): 42-48
 - **Sarcoma Resection With and Without Vascular Reconstruction: A Matched Case-control Study.** *Annals of surgery*
Poultides, G. A., Tran, T. B., Zambrano, E., Janson, L., Mohler, D. G., Mell, M. W., Avedian, R. S., Visser, B. C., Lee, J. T., Ganjoo, K., Harris, E. J., Norton, J. A.
2015; 262 (4): 632-40
 - **Effects of denosumab on pain and analgesic use in giant cell tumor of bone: Interim results from a phase II study** *ACTA ONCOLOGICA*
Martin-Broto, J., Cleeland, C. S., Glare, P. A., Engellau, J., Skubit, K. M., Blum, R. H., Ganjoo, K. N., Staddon, A., Dominkus, M., Feng, A., Qian, Y., Braun, A., Jacobs, et al
2014; 53 (9): 1173-1179
 - **Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.** *Journal of clinical oncology*
Levy, R., Ganjoo, K. N., Leonard, J. P., Vose, J. M., Flinn, I. W., Ambinder, R. F., Connors, J. M., Berinstein, N. L., Belch, A. R., Bartlett, N. L., Nichols, C., Emmanouilides, C. E., Timmerman, et al
2014; 32 (17): 1797-1803
 - **Results of SARC 022, a phase II multicenter study of linsitinib in pediatric and adult wild-type (WT) gastrointestinal stromal tumors (GIST).**
von Mehren, M., George, S., Heinrich, M. C., Schuetze, S., Belinsky, M. G., Janeway, K. A., Rink, L., Ganjoo, K. N., Yu, J., Yap, J. T., Wright, J., Van den Abbeele, A. D.
AMER SOC CLINICAL ONCOLOGY.2014
 - **Bevacizumab and cyclophosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404).** *Leukemia & lymphoma*
Ganjoo, K., Hong, F., Horning, S. J., Gascoyne, R. D., Natkunam, Y., Swinnen, L. J., Habermann, T. M., Kahl, B. S., Advani, R. H.
2014; 55 (4): 768-772
 - **Soft tissue sarcoma, version 2.2014.** *Journal of the National Comprehensive Cancer Network*
von Mehren, M., Randall, R. L., Benjamin, R. S., Boles, S., Bui, M. M., Casper, E. S., Conrad, E. U., DeLaney, T. F., Ganjoo, K. N., George, S., Gonzalez, R. J., Heslin, M. J., Kane, et al
2014; 12 (4): 473-483
 - **The Treatment Outcome for Adult Patients with Ewing's Sarcoma.** *Current oncology reports*
Ganjoo, K. N., Patel, S.
2013; 15 (4): 372-377
 - **Soft Tissue Sarcoma, Version 2.2012 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
von Mehren, M., Benjamin, R. S., Bui, M. M., Casper, E. S., Conrad, E. U., DeLaney, T. F., Ganjoo, K. N., George, S., Gonzalez, R., Heslin, M. J., Kane, J. M., Mayerson, J., McGarry, et al
2012; 10 (8): 951-960
 - **Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early-Stage Breast Cancer in a Young Woman With Li-Fraumeni Syndrome** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Henry, E., Villalobos, V., Million, L., Jensen, K. C., West, R., Ganjoo, K., Lebensohn, A., Ford, J. M., Telli, M. L.
2012; 10 (8): 939-942

- **Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial** *LEUKEMIA & LYMPHOMA*
Advani, R. H., Hong, F., Horning, S. J., Kahl, B. S., Manola, J., Swinnen, L. J., Habermann, T. M., Ganjoo, K.
2012; 53 (4): 718-720
- **Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer** *CANCER INVESTIGATION*
Riess, J. W., Logan, A. C., Krupitskaya, Y., Padda, S., Clement-Duchene, C., Ganjoo, K., Colevas, A. D., San Pedro-Salcedo, M., Kuo, C. J., Wakelee, H. A.
2012; 30 (3): 231-235
- **Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in Fc gamma RIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma** *CLINICAL CANCER RESEARCH*
Forero-Torres, A., de Vos, S., Pohlman, B. L., Pashkevich, M., Cronier, D. M., Dang, N. H., Carpenter, S. P., Allan, B. W., Nelson, J. G., Slapak, C. A., Smith, M. R., Link, B. K., Wooldridge, et al
2012; 18 (5): 1395-1403
- **The Prognostic Value of Tumor-Associated Macrophages in Leiomyosarcoma A Single Institution Study** *AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS*
Ganjoo, K. N., Witten, D., Patel, M., Espinosa, I., La, T., Tibshirani, R., van de Rijn, M., Jacobs, C., West, R. B.
2011; 34 (1): 82-86
- **A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer** *JOURNAL OF THORACIC ONCOLOGY*
Clement-Duchene, C., Krupitskaya, Y., Ganjoo, K., Lavori, P., McMillan, A., Kumar, A., Zhao, G., Padda, S., Zhou, L., San Pedro-Salcedo, M., Colevas, A. D., Wakelee, H. A.
2010; 5 (11): 1821-1825
- **TH-302, a tumor selective hypoxia activated prodrug, complements and enhances chemotherapy treatment with gemcitabine, docetaxel, pemetrexed, and doxorubicin** *22nd European Organization for Research and Treatment of Cancer (EORTC)-National-Cancer-Institute(NCI)-American-Association-for-Cancer-Research(AACR) Symposium on Molecular Targets and Cancer Therapeutics*
Hart, C. P., Borad, M., Chawla, S. P., Infante, J. R., Ganjoo, K. N., Langmuir, V. K., KROLL, S., Curd, J. G.
PERGAMON-ELSEVIER SCIENCE LTD.2010: 124-24
- **I-131-Tositumomab (Bexxar (R)) vs. Y-90-Ibritumomab (Zevalin (R)) Therapy of Low-Grade Refractory/Relapsed Non-Hodgkin Lymphoma** *MOLECULAR IMAGING AND BIOLOGY*
Iagaru, A., Mitra, E. S., Ganjoo, K., Knox, S. J., Goris, M. L.
2010; 12 (2): 198-203
- **Bendamustine Is Effective Therapy in Patients With Rituximab-Refractory, Indolent B-cell Non-Hodgkin Lymphoma Results From a Multicenter Study** *CANCER*
Kahl, B. S., Bartlett, N. L., Leonard, J. P., Chen, L., Ganjoo, K., Williams, M. E., Czuczman, M. S., Robinson, K. S., Joyce, R., Van der Jagt, R. H., Cheson, B. D.
2010; 116 (1): 106-114
- **Breast Angiosarcoma: Case Series and Expression of Vascular Endothelial Growth Factor.** *Case reports in oncology*
Brar, R., West, R., Witten, D., Raman, B., Jacobs, C., Ganjoo, K.
2009; 2 (3): 242-250
- **Cardiac Toxicity Associated with the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin) in Combination with CROP (A-CHOP) Chemotherapy for Peripheral T Cell Lymphoma (PTCL): The ECOG 2404 Trial.**
Advani, R. H., Hong, F., Ganjoo, K. N., Manola, J. B., Swinnen, L. J., Habermann, T. M., Horning, S. J.
AMER SOC HEMATOLOGY.2009: 667
- **A phase II first line study of gemcitabine, carboplatin and bevacizumab in advanced stage non-squamous non-small cell lung cancer**
Clement-Duchene, C., Krupitskaya, Y., Ganjoo, K., Lavori, P., Kumar, A., Zhao, G., Padda, S., San Pedro-Salcedo, M., Wakelee, H.
LIPPINCOTT WILLIAMS & WILKINS.2009: S674-S674
- **Mid-treatment PET predicts progression in hypofractionated accelerated radiation therapy for lung tumors**
Chang, C. N., Fillion, E., Chapman, C., Rao, A., Wakelee, H., Ganjoo, K., Le, Q., Maxim, P., Quon, A., Graves, E. E., Loo, B. W.
LIPPINCOTT WILLIAMS & WILKINS.2009: S939-S939
- **Coordinate Expression of Colony-Stimulating Factor-1 and Colony-Stimulating Factor-1-Related Proteins Is Associated with Poor Prognosis in Gynecological and Nongynecological Leiomyosarcoma** *AMERICAN JOURNAL OF PATHOLOGY*

- Espinosa, I., Beck, A. H., Lee, C., Zhu, S., Montgomery, K. D., Marinelli, R. J., Ganjoo, K. N., Nielsen, T. O., Gilks, C. B., West, R. B., van de Rijn, M.
2009; 174 (6): 2347-2356
- **Opportunistic enteroviral meningoencephalitis: an unusual treatable complication of rituximab therapy** *LEUKEMIA & LYMPHOMA*
Ganjoo, K. N., Raman, R., Sobel, R. A., Pinto, H. A.
2009; 50 (4): 673-675
 - **Breast Angiosarcoma: Case Series and Expression of Vascular Endothelial Growth Factor** *CASE REPORTS IN ONCOLOGY*
Brar, R., West, R., Witten, D., Raman, B., Jacobs, C., Ganjoo, K.
2009; 2 (3): 242-50
 - **Breast angiosarcomas: Case series and expression of vascular endothelial growth factor** *Case Reports in Oncology*
Rondeep Brar, Robert West, Daniela Witten, Bhargav Raman, Charlotte Jacobs, Kristen Ganjoo
2009; 2: 242-50
 - **Preliminary results of a Phase I study of AME-133v, an Fc-engineered humanized monoclonal antibody, in low-affinity Fc gamma RIIIA patients with previously-treated follicular lymphoma**
Forero, A., de Vos, S., Pohlman, B., Enas, N., Ganjoo, K. N., Cronier, D., Dang, N. H., Carpenter, S. P., Smith, M. R., Link, B. K., Wooldridge, J. E.
AMER ASSOC CANCER RESEARCH.2008
 - **Results of a Phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin's lymph**
Levy, R., Robertson, M. J., Ganjoo, K., Leonard, J., Vose, J., Denney, D.
AMER ASSOC CANCER RESEARCH.2008
 - **The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients** *JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY*
Ganjoo, K. N., Moore, A. M., Orazi, A., Sen, J. A., Johnson, C. S., An, C. S.
2008; 134 (3): 381-387
 - **Review of erlotinib in the treatment of advanced non-small cell lung cancer** *Biologics; Targets & Therapy*
Kristen N Ganjoo, Heather Wakelee
2008
 - **Review of erlotinib in the treatment of advanced non-small cell lung cancer.** *Biologics : targets & therapy*
Ganjoo, K. N., Wakelee, H.
2007; 1 (4): 335-346
 - **Comparison of I-131-Tositumomab (Bexxar (R)) and Y-90-Ibritumomab (Zevalin (R)) therapy of refractory/relapsed non-Hodgkin lymphoma**
Iagaru, A., Zhu, H., Mari, C., Knox, S. J., Ganjoo, K., Goris, M. L.
SPRINGER.2007: S168
 - **Non-Hodgkin lymphoma of the breast** *CANCER*
Ganjoo, K., Advani, R., Mariappan, M. R., McMillan, A., Horning, S.
2007; 110 (1): 25-30
 - **Antiangiogenesis: A new approach to the treatment of lymphoma** *LEUKEMIA & LYMPHOMA*
Ganjoo, K.
2007; 48 (3): 454-455
 - **Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis** *LEUKEMIA & LYMPHOMA*
Ganjoo, K. N., An, C. S., Robertson, M. J., Gordon, L. I., Sen, J. A., Weisenbach, J., Li, S., Weller, E. A., Orazi, A., Horning, S. J.
2006; 47 (6): 998-1005
 - **Phase II clinical studies of denileukin diftotox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia** *CANCER*
Frankel, A. E., Surendranathan, A., Black, J. H., White, A., Ganjoo, K., Cripe, L. D.
2006; 106 (10): 2158-2164
 - **A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas - A hoosier oncology group study** *AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS*

Ganjoo, K. N., Robertson, M. J., Fisher, W., Jung, S. H., McClean, J., Huh, S. Y., Bufill, J., Williams, S., Cripe, L. D.
2005; 28 (2): 169-172

- **Unusual locations of involvement by malignancies - Case 1. Testicular plasmacytoma** *JOURNAL OF CLINICAL ONCOLOGY*
Shafiqat, A., Yum, M. N., Abanour, R., Ganjoo, K. N.
2003; 21 (17): 3368-3369
- **Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: A Hoosier Oncology Group study** *ONCOLOGY*
Schneider, B. P., Ganjoo, K. N., Seitz, D. E., Picus, J., Fata, F., Stoner, C., Calley, C., Loehrer, P. J.
2003; 65 (3): 218-223
- **A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: A Hoosier Oncology Group study** *ONCOLOGY*
Ganjoo, K. N., GORDON, M. S., Sandler, A. B., Warner, R. E., Fife, K., Poirier, S., Seshadri, R., Loehrer, P. J.
2002; 62 (4): 299-304
- **Germ cell tumor associated primitive neuroectodermal tumors** *JOURNAL OF UROLOGY*
Ganjoo, K. N., Foster, R. S., Michael, H., Donohue, J. P., Einhorn, L. H.
2001; 165 (5): 1514-1516
- **Results of modern therapy for patients with mediastinal nonseminomatous germ cell tumors** *35th Annual Meeting of the American-Society-of-Clinical-Oncology*
Ganjoo, K. N., Rieger, K. M., Kesler, K. A., Sharma, M., Heilman, D. K., Einhorn, L. H.
JOHN WILEY & SONS INC.2000: 1051-56
- **Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma** *35th Annual Meeting of the American-Society-of-Clinical-Oncology*
Ganjoo, K. N., Chan, R. J., Sharma, M., Einhorn, L. H.
AMER SOC CLINICAL ONCOLOGY.1999: 3457-60
- **Primary mediastinal nonseminomatous germ cell tumors: The influence of postchemotherapy pathology on long-term survival after surgery** *79th Annual Meeting of the American-Association-for-Thoracic-Surgery*
Kesler, K. A., Rieger, K. M., Ganjoo, K. N., Sharma, M., Fineberg, N. S., Einhorn, L. H., Brown, J. W.
MOSBY-ELSEVIER.1999: 692-700
- **Lung cancer presenting with solitary bone metastases - Case 1: Metastatic adenocarcinoma to the patella** *JOURNAL OF CLINICAL ONCOLOGY*
Ganjoo, K. N., Loyal, J. A., Cramer, H. M., Loehrer, P. J.
1999; 17 (9): 2995-2997